KLRC1 and neoplasm: Some Mabs target EGFR, HER2, IGF‐1R, HGF, and VEGF; others may be checkpoint inhibitors (including Mabs to PD‐1, CTLA4, and NKG2A) or tumor‐targeting Mabs such as U36 and Mab E48.